MyFinsight
Home
Blog
About
Proceeds, net of 1,725 and
2,757 expenses, from...
$33,489K
Proceeds from the
exercise of options
$16K
Net cash provided by
financing activities
$33,505K
Net (decrease)
increase in cash, cash...
-$9,389K
Canceled cashflow
$33,505K
Stock-based compensation
$2,256K
Accrued expenses and
other current...
$1,751K
Other non-current
assets
-$1,573K
Depreciation and
amortization
$619K
Lease liabilities and
right-of-use (rou) asset, net
$80K
Net cash used in
operating activities
-$42,243K
Canceled cashflow
$6,279K
Net cash used in
investing activities
-$587K
Effect of currency rate
change on cash
-$64K
Net loss
-$40,552K
Accounts receivable
$2,986K
Inventory, current and
non-current
$2,903K
Prepaid expenses and
other current assets
$1,485K
Accounts payable
-$596K
Purchase of property and
equipment
$587K
Back
Back
Cash Flow
Tonix Pharmaceuticals Holding Corp. (TNXP)
Tonix Pharmaceuticals Holding Corp. (TNXP)
source: myfinsight.com